This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy

This study has been completed.
Information provided by:
Maaynei Hayesha Medical Center Identifier:
First received: March 9, 2008
Last updated: March 19, 2008
Last verified: March 2008

In varicocele the venous pressure in the prostatic bed is increased .This may result in raised hydrostatic pressure which in turn may stimulate prostatic hypertrophy.

Restoring normal venous drainage is expected to lower hydrostatic pressure followed by inhibition of prostatic growth and possibly leading regression in prostatic dimensions.

Condition Intervention
Varicocele Procedure: Sclerotherapy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Varicocele and Hypertrophy of Prostate

Further study details as provided by Maaynei Hayesha Medical Center:

Primary Outcome Measures:
  • Safety performance of the procedure. Reduction of above 20% in prostatic calculated volume. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Reduction of above 20% in nocturia [ Time Frame: 1 year ]

Enrollment: 35
Study Start Date: September 2007
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Sclerotherapy
    Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
Detailed Description:

35 male patients, aged 45 years or older, with documented benign prostatic hypertrophy (BPH)and varicocele as visualized by ultrasound and/or termography examination will be enrolled.

Each patient will undergo a full urologic examination to exclude possible malignancy as well as a thorough medical examination to establish eligibility for treatment.

In all selected patients the varicocele will be obliterated by means of embolization of the spermatic veins.

The patients will be followed every three months by abdominal ultrasound as well as by serial PSA for a period of 6-12 months.


Ages Eligible for Study:   45 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male
  • Age > 45 < 80 years
  • BPH
  • Bilateral varicocele.

Exclusion Criteria:

  • Coagulation disturbance
  • CHF
  • Malignancy
  • Renal failure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00639899

Maaynei Hayeshua Medical Center
Bnei Brak, Israel, 51544
Sponsors and Collaborators
Maaynei Hayesha Medical Center
Principal Investigator: Uriel Levinger, MD Maaynei Hayeshua Medical Center
  More Information

Responsible Party: Dr Uriel Levinger, Maaynei Hayesha Medical Center Identifier: NCT00639899     History of Changes
Other Study ID Numbers: RVS-001-IL
Study First Received: March 9, 2008
Last Updated: March 19, 2008

Keywords provided by Maaynei Hayesha Medical Center:

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Genital Diseases, Male
Vascular Diseases
Cardiovascular Diseases processed this record on September 19, 2017